Pemphigoid is a group of subepidermal, blistering autoimmune diseases that primarily affect the skin, especially the lower abdomen, groin, and flexor surfaces of the extremities. Here, autoantibodies (anti-BPA-2 and anti-BPA-1) are directed against the basal layer of the epidermis and mucosa.
The condition tends to persist for months or years with periods of exacerbation and remission. Localized variants of the condition have been reported, most often limited to the lower extremities and usually affecting women.
The FJORD Study is being done to learn more about whether the study drug works to help improve bullous pemphigoid .
- The study is being done because treatment options for bullous pemphigoid are limited.
- The study drug has been approved in more than 50 countries for treating severe asthma.
- It will now be studied to see if it improves the symptoms of bullous pemphigoid.
Study Volunteers Must Meet the Following Criteria
- Males and females
- Ages 18 and above diagnosed with bullus pemphigoid
- Must have symptoms such as blisters and itching
Study Participant Expectations
- Study is 10 month duration
- Attend study center visits every 4 weeks to receive an injection of study drug or placebo
- Complete a daily diary of your symptoms
- There is no cost to participate.
- Patients who qualify may be compensated for time and travel